John, Luis H.
Fridgeirsson, Egill A.
Kors, Jan A.
Reps, Jenna M.
Williams, Ross D.
Ryan, Patrick B.
Rijnbeek, Peter R.
Article History
Received: 27 October 2023
Accepted: 15 July 2024
First Online: 29 July 2024
Declarations
:
: All patient data included in this study were deidentified. The New England Institutional Review Board determined that studies conducted in Optum, IBM MDCR, and Iqvia Germany are exempt from study-specific IRB review, as these studies do not qualify as human subjects research. IPCI (study reference 2/2022) had institutional review board approval for the analysis, or used deidentified data, and thus the analysis was determined not to be human subjects research and informed consent was not deemed necessary at this site.
: Not applicable.
: Jenna M. Reps and Patrick B. Ryan are employees of Janssen Research & Development and shareholder of Johnson & Johnson. Peter R. Rijnbeek, Egill A. Fridgeirsson, Luis H. John, Jan A. Kors, Jenna M. Reps, and Ross D. Williams work for a research group that in the past 3 years receives/received unconditional research grants from Chiesi, UCB, Amgen, Johnson and Johnson, Innovative Medicines Initiative, and the European Medicines Agency. None of these grants results in a conflict of interest to the content of this paper.